Enfuvirtide
- Generic Name
- Enfuvirtide
- Brand Names
- Fuzeon
- Drug Type
- Biotech
- CAS Number
- 159519-65-0
- Unique Ingredient Identifier
- 19OWO1T3ZE
- Background
Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
- Indication
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy
- Conditions
- HIV Infections
- Interventions
- Drug: Efavirenz, lamivudine, and tenofovir
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 2
- Registration Number
- NCT00344760
- Locations
- 🇺🇸
University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 326
- Registration Number
- NCT00337701
Fuzeon Viral Decay Pilot Study
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Canadian Immunodeficiency Research Collaborative
- Target Recruit Count
- 18
- Registration Number
- NCT00334022
- Locations
- 🇨🇦
Maple Leaf Medical Clinic, Toronto, Ontario, Canada
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 142
- Registration Number
- NCT00326963
Study of Valproic Acid to Treat HIV Infected Adults
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 14
- Registration Number
- NCT00312546
- Locations
- 🇺🇸
University of North Carolina Memorial Hospital, Chapel Hill, North Carolina, United States
Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)
- Conditions
- HIV InfectionsAIDS
- Interventions
- First Posted Date
- 2006-03-15
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Target Recruit Count
- 195
- Registration Number
- NCT00302822
- Locations
- 🇫🇷
Service des Maladies Infectieuses A Hôpital Bichat-Claude Bernard, Paris, France
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT00233883
QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 361
- Registration Number
- NCT00232908
Cohort Study for Patients Using Fuzeon (Enfuvirtide)
- Conditions
- Antiretroviral TreatmentHIV Infections
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2005-10-25
- Lead Sponsor
- Institute for Interdisciplinary Infectiology
- Target Recruit Count
- 200
- Registration Number
- NCT00216359
- Locations
- 🇩🇪
Ifi-Institute for Interdisciplinary Infectiology, Hamburg, Germany
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
- Conditions
- HIV-Associated Lipodystrophy SyndromeCardiovascular Disease
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00192660
- Locations
- 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.